景峯醫藥(000908.SZ):子公司來曲唑片獲批上市
格隆匯6月10日丨景峯醫藥(000908.SZ)宣佈,近日,公司子公司海南錦瑞製藥有限公司獲得國家藥監局核准簽發的化學藥品“來曲唑片”的《藥品註冊批件》。
來曲唑是一種選擇性的、非甾體類的芳香化酶抑制劑,它對糖皮質激素和鹽皮質激素的分泌以及甲狀腺功能沒有負面影響。它可以競爭性地與細胞色素P450酶亞單位的血紅素結合,從而抑制芳香化酶,導致雌激素在所有組織中的生物合成減少。
該藥品主要用於已經接受他莫昔芬輔助治療5年、絕經後早期乳腺癌患者的輔助治療或絕經後早期乳腺癌患者的輔助治療,此類患者雌激素或孕激素受體陽性。也適用於治療絕經後、雌激素受體陽性、孕激素受體陽性或受體狀況不明的晚期乳腺癌患者,這些患者為自然絕經或人工誘導絕經。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.